Revolution Medicines starts phase 3 trial of zoldonrasib in pancreatic cancer

• Revolution Medicines has started treating patients in its global Phase 3 trial of zoldonrasib for pancreatic cancer.
• Shares of the company moved upward to $165.81 following the operational update.
• The study forms a core part of the firm's broader strategy to deliver targeted therapies for RAS-mutated tumors.

Revolution Medicines (NASDAQ:RVMD) began dosing patients in its global Phase 3 RASolute 305 trial for metastatic pancreatic cancer.

This late-stage evaluation follows positive earlier developments in the company's RAS-mutant oncology research programs over the past year.

The double-blind study evaluates the oral drug zoldonrasib alongside investigator-selected chemotherapy drugs against a standard placebo combination.

The company stated that primary goals are focused strictly on determining overall survival and progression-free survival metrics.

Following the announcement, Revolution Medicines' share price was up at $165.81.

The oncology specialist focuses entirely on discovering and developing targeted therapies for patients living with complex RAS-mutant cancers.

This specific global study marks the latest regulatory milestone for the business as it expands its active clinical pipeline.